Media ReleasesChimeric Therapeutics

View All Chimeric Therapeutics News


Chimeric Therapeutics - Completion of retail component of Entitlement Offer


On 21 February 2022, Chimeric Therapeutics Limited (ASX:CHM) (Chimeric or Company) announced the details of an accelerated non-renounceable entitlement offer (Entitlement Offer) to raise approximately $18 million (before costs of the offer).

Chimeric announced the successful completion of the Institutional component of the Entitlement Offer on 23 February 2022, which raised approximately $7.4 million, and the Retail Entitlement Offer closed on 18 March 2022, raising approximately $4.3 million, bringing the total raise for the Entitlement Offer to $11.7 million.   

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.